Current Oncology (Nov 2024)

Exploiting Integrin-αVβ3 to Enhance Radiotherapy Efficacy in Medulloblastoma via Ferroptosis

  • Célia Gotorbe,
  • Fabien Segui,
  • William Echavidre,
  • Jérôme Durivault,
  • Thays Blanchard,
  • Valérie Vial,
  • Marina Pagnuzzi-Boncompagni,
  • Rémy Villeneuve,
  • Régis Amblard,
  • Nicolas Garnier,
  • Cécile Ortholan,
  • Benjamin Serrano,
  • Vincent Picco,
  • Jacques Pouysségur,
  • Milica Vucetic,
  • Christopher Montemagno

DOI
https://doi.org/10.3390/curroncol31110545
Journal volume & issue
Vol. 31, no. 11
pp. 7390 – 7402

Abstract

Read online

Medulloblastoma, a malignant pediatric brain tumor, has a poor prognosis upon relapse, highlighting a critical clinical need. Our previous research linked medulloblastoma cell radioresistance to integrin-αvβ3 expression. β3-depleted (β3_KO) medulloblastoma cells exhibit lipid hydroxyperoxide accumulation after radiotherapy, indicating ferroptosis, a regulated cell death induced by ROS and inhibited by antioxidants such as cysteine, glutathione (GSH), and glutathione peroxidase 4 (GPx4). However, the link between αvβ3 expression, ferroptosis inhibition, and sensitivity to radiotherapy remains unclear. We showed that irradiated β3_KO medulloblastoma cells primarily die by ferroptosis, with β3-subunit expression correlating with radiotherapy sensitivity and anti-ferroptotic protein levels. Our findings suggest that integrin-αvβ3 signaling boosts oxidative stress resilience via mTORC1. Thus, targeting integrin-αvβ3 could enhance radiotherapy efficacy in medulloblastoma by inducing ferroptotic cell death.

Keywords